Welcome to our dedicated page for Adagio Medical news (Ticker: ADGM), a resource for investors and traders seeking the latest updates and insights on Adagio Medical stock.
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) is a medical device company focused on catheter ablation technologies for cardiac arrhythmias, and its news flow centers on the development, clinical evaluation, and commercialization of its Ultra-Low Temperature Cryoablation (ULTC) platform. Company press releases highlight progress with the vCLAS Cryoablation System for ventricular tachycardia, key clinical milestones, financing events, and leadership updates.
Investors and clinicians following ADGM news will see regular updates on the FULCRUM-VT U.S. pivotal IDE study, which Adagio describes as a prospective, multi-center, open-label, single-arm trial designed to evaluate the safety and effectiveness of ULTC for recurring monomorphic ventricular tachycardia. News items include completion of enrollment, preliminary acute safety and effectiveness results presented at a major ventricular arrhythmia symposium, and plans to use study outcomes to support a future PMA application for vCLAS.
Adagio’s news releases also cover capital markets activity, such as the announcement and closing of a private placement intended to fund FDA submission activities, next-generation ULTC catheter development, and expansion of manufacturing and commercial readiness. Additional coverage includes governance and leadership changes, including the appointment of a Chief Business Officer who also serves as Chief Financial Officer, the addition of an industry veteran to the Board of Directors, and the hiring of senior executives in global sales and manufacturing and operations.
For those tracking ADGM, the news stream provides insight into clinical data disclosures, regulatory strategy, financing transactions, conference presentations, and board and management developments that the company identifies as important to its ULTC-based ventricular tachycardia program.
Adagio Medical (Nasdaq: ADGM) said its management team will participate in the 25th Annual Needham Virtual Conference held April 13–16, 2026. The presentation provides an investor-facing opportunity to discuss the company’s catheter ablation technologies and strategic progress.
Adagio Medical (Nasdaq: ADGM) announced that pivotal results from the FULCRUM-VT IDE trial evaluating Ultra-Low Temperature Ablation (ULTA) for scar-related ventricular tachycardia were accepted for a late-breaking clinical science session at Heart Rhythm 2026.
The presentation is scheduled for April 26, 2026 at 8:30 a.m. CT with Dr. Atul Verma presenting. Adagio will host an investor webcast on April 27, 2026 at 8:00 a.m. ET to review results and take questions.
Adagio Medical (Nasdaq: ADGM) reported fourth-quarter and full-year 2025 results and clinical progress. Key milestones include completion of 209-patient FULCRUM-VT pivotal IDE enrollment, preliminary 97% acute effectiveness, peer-reviewed ULTA publication, 13 Expanded Access vCLAS cases, board and executive hires, and a private placement up to $50M with ~$19M upfront.
Financials: 2025 net loss $25.1M, Q4 net loss $3.3M, and cash of $17.1M at December 31, 2025.
Adagio Medical (Nasdaq: ADGM) published pre-clinical results for its next-generation ULTA ventricular ablation catheter on March 24, 2026. The paper reports improved handling with an 8.5 French catheter, single-freeze ablations at ~-170°C, and lesion performance: 5 mm in 15s and 12.5 mm in ~120s.
Authors noted potential procedural gains including a 50–75% reduction in ablation time and up to 30 minutes shorter procedures versus first-generation ULTA in pre-clinical models.
Adagio Medical (Nasdaq: ADGM) reported completion of 13 ventricular ablation procedures using its vCLAS ULTA cryoablation system under FDA Expanded Access for patients with recurrent VT or symptomatic PVCs who failed prior therapies. The company says FULCRUM-VT fully enrolled in October 2025 and expects U.S. regulatory approval by year-end 2026.
Physicians reported favorable acute procedural outcomes and integration into EP lab workflow; PVC cases expand the platform's potential reach within the VT ablation market.
Adagio Medical (NASDAQ: ADGM) will participate in the 38th Annual Roth Conference on March 23-24, 2026 in Laguna Niguel, CA. Management will host one-on-one investor meetings during the event. Contact your ROTH representative or email ir@adagiomedical.com to schedule a meeting.
Adagio Medical (Nasdaq: ADGM) will present at the TD Cowen 46th Annual Healthcare Conference on March 3, 2026 at 2:30 PM ET in Boston. A live webcast and replay will be available via the event platform and on the company investor website.
Investors can watch the presentation live or access the replay at the company's investor relations site.
Adagio Medical (Nasdaq: ADGM) published U.S. Early Feasibility Study results showing favorable safety and performance for ultralow temperature cardiac ablation (ULTC) in scar-related ventricular tachycardia.
In 20 patients across four U.S. centers, no device- or procedure-related major adverse events were seen at 7 and 30 days; 92.9% non-inducibility among 14 tested; 72% reduced or stopped antiarrhythmic drugs; 83.3% free from ICD shock at mean 24-week follow-up.
Adagio Medical (Nasdaq: ADGM) said management will present at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 10, 2026 in Snowbird, Utah.
The participation highlights investor outreach and provides a forum to discuss product development and corporate strategy.
Adagio Medical (Nasdaq: ADGM) announced two senior hires to accelerate commercial readiness for its Ultra-Low Temperature Cardiac Ablation (ULTC) platform: Marie-Claude Jacques as Senior Vice President, Global Sales, and Antwan Gipson as Senior Vice President, Manufacturing & Operations, effective December 22, 2025.
Key points: Ms. Jacques brings 15+ years in electrophysiology and interventional cardiology, led a 100-person sales organization at Baylis and helped scale its EP portfolio to over $170 million in annual revenue. Mr. Gipson brings 20+ years in manufacturing and operations, citing prior scale-ups of production 10–100x and cost-of-goods reductions up to 75%. Management said these hires support planned commercialization in 2026.